Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) Director Sells $806,300.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Director Patrick Walsh sold 10,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $80.63, for a total transaction of $806,300.00. Following the transaction, the director owned 38,432 shares of the company’s stock, valued at $3,098,772.16. This represents a 20.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

ANI Pharmaceuticals Price Performance

Shares of NASDAQ:ANIP opened at $78.01 on Friday. The company has a quick ratio of 2.52, a current ratio of 3.12 and a debt-to-equity ratio of 1.06. The firm has a market capitalization of $1.77 billion, a PE ratio of 19.75 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The company has a 50-day moving average price of $77.29 and a two-hundred day moving average price of $80.48.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The firm had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company’s quarterly revenue was up 20.5% on a year-over-year basis. During the same quarter last year, the business earned $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership bought a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $32,992,000. Balyasny Asset Management L.P. lifted its position in ANI Pharmaceuticals by 2,785.7% during the third quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the last quarter. Divisadero Street Capital Management LP bought a new stake in ANI Pharmaceuticals during the third quarter valued at approximately $21,454,000. Rubric Capital Management LP lifted its position in ANI Pharmaceuticals by 354.7% during the second quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the last quarter. Finally, UBS Group AG lifted its position in ANI Pharmaceuticals by 45.8% during the third quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ANIP shares. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Finally, Guggenheim raised their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.